Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Ironwood Pharmaceuticals Cash on Hand 2010-2024 | IRWD

Ironwood Pharmaceuticals cash on hand from 2010 to 2024. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
  
Ironwood Pharmaceuticals Annual Cash on Hand
(Millions of US $)
2023 $92
2022 $657
2021 $621
2020 $364
2019 $178
2018 $174
2017 $221
2016 $305
2015 $439
2014 $248
2013 $198
2012 $168
2011 $164
2010 $251
2009 $122
Ironwood Pharmaceuticals Quarterly Cash on Hand
(Millions of US $)
2024-06-30 $106
2024-03-31 $122
2023-12-31 $92
2023-09-30 $111
2023-06-30 $176
2023-03-31 $742
2022-12-31 $657
2022-09-30 $575
2022-06-30 $506
2022-03-31 $595
2021-12-31 $621
2021-09-30 $576
2021-06-30 $494
2021-03-31 $440
2020-12-31 $364
2020-09-30 $309
2020-06-30 $255
2020-03-31 $232
2019-12-31 $178
2019-09-30 $147
2019-06-30 $107
2019-03-31 $120
2018-12-31 $174
2018-09-30 $161
2018-06-30 $181
2018-03-31 $194
2017-12-31 $221
2017-09-30 $225
2017-06-30 $273
2017-03-31 $297
2016-12-31 $305
2016-09-30 $320
2016-06-30 $325
2016-03-31 $435
2015-12-31 $439
2015-09-30 $462
2015-06-30 $493
2015-03-31 $216
2014-12-31 $248
2014-09-30 $265
2014-06-30 $302
2014-03-31 $332
2013-12-31 $198
2013-09-30 $242
2013-06-30 $301
2013-03-31 $242
2012-12-31 $168
2012-09-30 $193
2012-06-30 $158
2012-03-31 $202
2011-12-31 $164
2011-09-30 $175
2011-06-30 $201
2011-03-31 $221
2010-12-31 $251
2010-09-30 $254
2010-06-30 $272
2010-03-31 $299
2009-12-31 $122
2009-09-30 $99
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.674B $0.443B
Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $79.017B 30.41
Takeda Pharmaceutical (TAK) Japan $43.337B 9.02
Sandoz Group AG (SDZNY) Switzerland $19.524B 0.00
Merck (MKKGY) Germany $19.470B 17.44
Astellas Pharma (ALPMY) Japan $19.363B 17.83
United Therapeutics (UTHR) United States $16.217B 15.95
Summit Therapeutics (SMMT) United States $13.503B 0.00
Shionogi (SGIOY) Japan $12.119B 11.61
Neurocrine Biosciences (NBIX) United States $11.890B 31.49
Catalent (CTLT) United States $10.727B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $7.354B 7.19
Orion OYJ (ORINY) Finland $6.653B 18.71
Madrigal Pharmaceuticals (MDGL) United States $6.294B 0.00
Corcept Therapeutics (CORT) United States $5.431B 41.13
Ionis Pharmaceuticals (IONS) United States $5.422B 0.00
Crinetics Pharmaceuticals (CRNX) United States $5.075B 0.00
PTC Therapeutics (PTCT) United States $3.026B 0.00
Dyne Therapeutics (DYN) United States $2.889B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.622B 15.69
Catalyst Pharmaceuticals (CPRX) United States $2.457B 11.14
Arrowhead Pharmaceuticals (ARWR) United States $2.309B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $2.300B 0.00
Soleno Therapeutics (SLNO) United States $2.233B 0.00
Evotec AG (EVO) Germany $1.928B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $1.813B 0.00
Recursion Pharmaceuticals (RXRX) United States $1.770B 0.00
Xencor (XNCR) United States $1.614B 0.00
BioCryst Pharmaceuticals (BCRX) United States $1.456B 0.00
Ocular Therapeutix (OCUL) United States $1.440B 0.00
Harrow (HROW) United States $1.389B 0.00
ARS Pharmaceuticals (SPRY) United States $1.362B 0.00
Indivior (INDV) United States $1.354B 5.52
Guardian Pharmacy Services (GRDN) United States $1.300B 0.00
Cassava Sciences (SAVA) United States $1.295B 0.00
Enliven Therapeutics (ELVN) United States $1.193B 0.00
Ardelyx (ARDX) United States $1.177B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.163B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $1.050B 0.00
Collegium Pharmaceutical (COLL) United States $0.954B 5.21
Bioventus (BVS) United States $0.912B 28.82
Relay Therapeutics (RLAY) United States $0.854B 0.00
USANA Health Sciences (USNA) United States $0.769B 14.25
Cronos Group (CRON) Canada $0.768B 0.00
Tourmaline Bio (TRML) United States $0.650B 0.00
Exscientia (EXAI) United Kingdom $0.613B 0.00
Elite Pharmaceuticals (ELTP) United States $0.600B 0.00
Altimmune (ALT) United States $0.541B 0.00
Organogenesis (ORGO) United States $0.512B 0.00
Savara (SVRA) United States $0.511B 0.00
ProKidney (PROK) United States $0.491B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.468B 0.00
Zevra Therapeutics (ZVRA) United States $0.460B 0.00
OmniAb (OABI) United States $0.458B 0.00
Korro Bio (KRRO) United States $0.446B 0.00
Xeris Biopharma Holdings (XERS) United States $0.435B 0.00
Larimar Therapeutics (LRMR) United States $0.427B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.425B 172.14
Siga Technologies (SIGA) United States $0.424B 4.95
Esperion Therapeutics (ESPR) United States $0.418B 0.00
KalVista Pharmaceuticals (KALV) United States $0.410B 0.00
4D Molecular Therapeutics (FDMT) United States $0.408B 0.00
Verve Therapeutics (VERV) United States $0.406B 0.00
Aquestive Therapeutics (AQST) United States $0.405B 0.00
Akebia Therapeutics (AKBA) United States $0.391B 0.00
Silence Therapeutics (SLN) United Kingdom $0.380B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.326B 0.00
Avita Medical (RCEL) United States $0.313B 0.00
Sage Therapeutics (SAGE) United States $0.312B 0.00
Lyell Immunopharma (LYEL) United States $0.307B 0.00
Nature's Sunshine Products (NATR) United States $0.296B 17.58
Aldeyra Therapeutics (ALDX) United States $0.251B 0.00
Pyxis Oncology (PYXS) United States $0.249B 0.00
Lexeo Therapeutics (LXEO) United States $0.220B 0.00
Acrivon Therapeutics (ACRV) United States $0.217B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.202B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.202B 0.00
Profound Medical (PROF) Canada $0.198B 0.00
Nektar Therapeutics (NKTR) United States $0.197B 0.00
Nanobiotix S.A (NBTX) France $0.185B 0.00
Heron Therapeutics (HRTX) United States $0.181B 0.00
Galectin Therapeutics (GALT) United States $0.174B 0.00
MediWound (MDWD) Israel $0.173B 0.00
Cardiol Therapeutics (CRDL) Canada $0.149B 0.00
CytoDyn (CYDY) United States $0.148B 0.00
Aclaris Therapeutics (ACRS) United States $0.146B 0.00
Achieve Life Sciences (ACHV) Canada $0.146B 0.00
Context Therapeutics (CNTX) United States $0.138B 0.00
Avalo Therapeutics (AVTX) United States $0.129B 0.00
Incannex Healthcare (IXHL) Australia $0.127B 0.00
Telomir Pharmaceuticals (TELO) United States $0.110B 0.00
Journey Medical (DERM) United States $0.107B 0.00
Century Therapeutics (IPSC) United States $0.104B 0.00
VAXART, INC (VXRT) United States $0.103B 0.00
Innate Pharma SA (IPHYF) France $0.103B 0.00
Karyopharm Therapeutics (KPTI) United States $0.102B 0.00
Fractyl Health (GUTS) United States $0.095B 0.00
Regulus Therapeutics (RGLS) United States $0.094B 0.00
Arch Biopartners (ACHFF) Canada $0.092B 0.00
Relmada Therapeutics (RLMD) United States $0.091B 0.00
PMV Pharmaceuticals (PMVP) United States $0.083B 0.00
CASI Pharmaceuticals (CASI) China $0.082B 0.00
Vivani Medical (VANI) United States $0.078B 0.00
Assertio Holdings (ASRT) United States $0.077B 20.28
ESSA Pharma (EPIX) Canada $0.076B 0.00
Swiftmerge Acquisition (IVCP) United States $0.076B 0.00
ElectroCore (ECOR) United States $0.072B 0.00
Inotiv (NOTV) United States $0.070B 0.00
Scienture Holdings (SCNX) United States $0.069B 0.00
Metagenomi (MGX) United States $0.068B 0.00
AlloVir (ALVR) United States $0.066B 0.00
OptiNose (OPTN) United States $0.066B 0.00
Champions Oncology (CSBR) United States $0.061B 0.00
Mural Oncology (MURA) Ireland $0.059B 0.00
Prelude Therapeutics (PRLD) United States $0.057B 0.00
Nutriband (NTRB) United States $0.053B 0.00
Protara Therapeutics (TARA) United States $0.051B 0.00
Gain Therapeutics (GANX) United States $0.049B 0.00
Unicycive Therapeutics (UNCY) United States $0.048B 0.00
SCYNEXIS (SCYX) United States $0.046B 0.00
Rafael Holdings (RFL) United States $0.045B 0.00
VYNE Therapeutics (VYNE) United States $0.040B 0.00
BioLineRx (BLRX) Israel $0.038B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.038B 0.00
Iterum Therapeutics (ITRM) Ireland $0.038B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.038B 0.00
Carisma Therapeutics (CARM) United States $0.037B 0.00
Citius Pharmaceuticals (CTXR) United States $0.036B 0.00
FibroGen (FGEN) United States $0.034B 0.00
DURECT (DRRX) United States $0.031B 0.00
BioVie (BIVI) United States $0.030B 0.00
Surrozen (SRZN) United States $0.029B 0.00
Oruka Therapeutics (ORKA) United States $0.029B 0.00
Natural Alternatives (NAII) United States $0.028B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.027B 0.00
GlycoMimetics (GLYC) United States $0.027B 0.00
Lipocine (LPCN) United States $0.026B 0.00
Enlivex Therapeutics (ENLV) Israel $0.023B 0.00
Tempest Therapeutics (TPST) United States $0.022B 0.00
MEI Pharma (MEIP) United States $0.019B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.018B 0.00
ProPhase Labs (PRPH) United States $0.018B 0.00
PolyPid (PYPD) Israel $0.017B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.017B 0.00
TherapeuticsMD (TXMD) United States $0.016B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.016B 0.00
Mannatech (MTEX) United States $0.016B 0.00
Minerva Neurosciences (NERV) United States $0.015B 0.00
Inhibikase Therapeutics (IKT) United States $0.015B 0.00
Cosmos Health (COSM) United States $0.015B 0.00
NRx Pharmaceuticals (NRXP) United States $0.014B 0.00
Vivos Therapeutics (VVOS) United States $0.014B 0.00
Nuvilex (PMCB) United States $0.013B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.012B 0.00
Talphera (TLPH) United States $0.012B 0.00
Indaptus Therapeutics (INDP) United States $0.011B 0.00
Lyra Therapeutics (LYRA) United States $0.011B 0.00
Dominari Holdings (DOMH) United States $0.011B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.010B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.010B 0.00
Redhill Biopharma (RDHL) Israel $0.009B 0.00
Traws Pharma (TRAW) United States $0.009B 0.00
Jaguar Animal Health (JAGX) United States $0.009B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
Conduit Pharmaceuticals (CDT) United States $0.008B 0.00
Plus Therapeutics (PSTV) United States $0.007B 0.00
Ainos (AIMD) United States $0.006B 0.00
Viracta Therapeutics (VIRX) United States $0.006B 0.00
Biomerica (BMRA) United States $0.006B 0.00
TransCode Therapeutics (RNAZ) United States $0.006B 0.00
Mangoceuticals (MGRX) United States $0.006B 0.00
Klotho Neurosciences (KLTO) United States $0.006B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
SHINECO (SISI) China $0.004B 0.00
Avenue Therapeutics (ATXI) United States $0.004B 0.11
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.004B 0.00
Aptorum Group (APM) United Kingdom $0.004B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.003B 0.00
Oncternal Therapeutics (ONCT) United States $0.003B 0.00
Alaunos Therapeutics (TCRT) United States $0.003B 0.00
Heatwurx (PCSA) United States $0.003B 0.00
TNF Pharmaceuticals (TNFA) United States $0.003B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.003B 0.00
Molecular Templates (MTEM) United States $0.003B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
Petros Pharmaceuticals (PTPI) United States $0.003B 0.00
XORTX Therapeutics (XRTX) Canada $0.003B 0.00
SciSparc (SPRC) Israel $0.002B 0.00
Phio Pharmaceuticals (PHIO) United States $0.002B 0.00
Clearmind Medicine (CMND) Canada $0.002B 0.00
Bio-Path Holdings (BPTH) United States $0.002B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.002B 0.00
China SXT Pharmaceuticals (SXTC) China $0.002B 0.00
Altamira Therapeutics (CYTO) Bermuda $0.002B 0.00
Aditxt (ADTX) United States $0.001B 0.00
Qualigen Therapeutics (QLGN) United States $0.001B 0.00
Universe Pharmaceuticals INC (UPC) China $0.001B 0.00
PainReform (PRFX) Israel $0.000B 0.00
CERo Therapeutics Holdings (CERO) United States $0.000B 0.00
Grifols, S.A (GRFS) Spain $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
Procaps Group, S.A (PROC) Luxembourg $0.000B 1.33
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Stevanato Group S.p.A (STVN) Italy $0.000B 37.26